March 14, 2014
This article was reported by Washington Post.
The Washington Post reported that the California Technology Assessment Forum convened a 15-member panel of experts to weigh evidence on new hepatitis C treatments that cost from $66,000 to $84,000 per patient. The panel noted that although the new drugs -- Gilead Sciences' Sovaldi and Johnson & Johnson's Olysio -- could be more effective than older treatments, their cost could undermine their value to the health system. Sovaldi cost $1,000 for each pill, and Olysio cost slightly less.
Panel members representing hospitals, insurers, and patient advocates agreed that not every hepatitis C-infected person should receive immediate treatment with the new drugs. Rena K. Fox, professor of medicine at the University of California, San Francisco, urged companies to reduce the drugs' prices to avoid forcing healthcare providers to decide which patients' needs were the most urgent. The experts noted that additional treatments would be available within a year, and people with little or no liver damage could choose to wait.
Ryan Clary, executive director of the National Viral Hepatitis Roundtable (NVHR), stated that patients were more concerned about their health than about bankrupting the healthcare system. NVHR was a consumer group that received some funding from the drug industry.
Private insurers and Medicaid were considering how to cover the new drugs. Strategies under consideration included requiring prior authorization or limiting use of the new drugs to the sickest patients. Some Medicaid insurers were seeking additional funding from states. The panel would publish their recommendations for prioritizing patients for the new drugs and their comparison of the new drugs' effectiveness with older drugs in approximately one month.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Gay Men Cannot Get HIV From Partners Who Are Virally Suppressed, New Study Proves|
|PrEP Before and After Sex Worked as Well as Daily PrEP in Preventing HIV, New Study Finds|
|How Will Long-Acting HIV Antiretrovirals Work in the Real World?|
|Reported "PrEP Failure" in Thailand May Be a Result of Missing Acute HIV Infection: Here's What You Need to Know|
|This Week in HIV Research: At-Home PrEP Care Advances|